Market Cap 18.53M
Revenue (ttm) 0.00
Net Income (ttm) -13.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 65,300
Avg Vol 53,364
Day's Range N/A - N/A
Shares Out 3.08M
Stochastic %K 43%
Beta 1.81
Analysts Strong Sell
Price Target $27.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
VanguardVestor
VanguardVestor May. 9 at 7:38 AM
$CVKD Biotechnology company dependent on clinical progress and financing conditions
0 · Reply
MarionGoodwin12
MarionGoodwin12 May. 9 at 5:03 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MRAM $NVO
0 · Reply
JaniceThomas11
JaniceThomas11 May. 9 at 4:43 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $IBRX $IREN
0 · Reply
MarionCampbell23
MarionCampbell23 May. 9 at 3:42 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $AMD $RKLB
0 · Reply
LatashaWhite63
LatashaWhite63 May. 9 at 3:38 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $SNDK $TSLA
0 · Reply
MaryFishmana
MaryFishmana May. 9 at 3:27 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MU $INTC
0 · Reply
JeanMurphy55
JeanMurphy55 May. 9 at 3:19 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $NVO $EEM
0 · Reply
CarolHerrick66
CarolHerrick66 May. 9 at 3:06 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MRAM $STFS
1 · Reply
ZacksSCR
ZacksSCR May. 8 at 4:17 PM
$CVKD Designing Phase 3 Trial for CAD-1005 in HIT https://buff.ly/BXrJgse
0 · Reply
ChasityCruz14
ChasityCruz14 May. 8 at 4:03 PM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $IREN $MRNA
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics Inc trading resumes

2026-04-01T19:35:16.000Z - 5 weeks ago

Cadrenal Therapeutics Inc trading resumes


Cadrenal Therapeutics highlights research on 12-LOX inhibition

2026-03-12T12:21:38.000Z - 2 months ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition


Cadrenal Therapeutics announces Phase 2 results for CAD-1005

2026-02-24T13:39:32.000Z - 2 months ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005


Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 11:00 AM EST - 5 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud


Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

2025-08-11T12:20:21.000Z - 9 months ago

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)


Cadrenal Therapeutics announces trial plans for tecarfarin

2025-08-05T10:25:11.000Z - 9 months ago

Cadrenal Therapeutics announces trial plans for tecarfarin


Cadrenal Therapeutics  teams with Abbott inTECH-LVAD trial

2025-03-04T13:21:36.000Z - 1 year ago

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

ABT


VanguardVestor
VanguardVestor May. 9 at 7:38 AM
$CVKD Biotechnology company dependent on clinical progress and financing conditions
0 · Reply
MarionGoodwin12
MarionGoodwin12 May. 9 at 5:03 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MRAM $NVO
0 · Reply
JaniceThomas11
JaniceThomas11 May. 9 at 4:43 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $IBRX $IREN
0 · Reply
MarionCampbell23
MarionCampbell23 May. 9 at 3:42 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $AMD $RKLB
0 · Reply
LatashaWhite63
LatashaWhite63 May. 9 at 3:38 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $SNDK $TSLA
0 · Reply
MaryFishmana
MaryFishmana May. 9 at 3:27 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MU $INTC
0 · Reply
JeanMurphy55
JeanMurphy55 May. 9 at 3:19 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $NVO $EEM
0 · Reply
CarolHerrick66
CarolHerrick66 May. 9 at 3:06 AM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $MRAM $STFS
1 · Reply
ZacksSCR
ZacksSCR May. 8 at 4:17 PM
$CVKD Designing Phase 3 Trial for CAD-1005 in HIT https://buff.ly/BXrJgse
0 · Reply
ChasityCruz14
ChasityCruz14 May. 8 at 4:03 PM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $IREN $MRNA
0 · Reply
ChasityCruz14
ChasityCruz14 May. 8 at 4:00 PM
$CVKD Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-reports-first-quarter-123000450.html $RXT $RILY
1 · Reply
options1315
options1315 May. 8 at 2:19 AM
$CVKD scam. I knew it the first time all the scam bots started pumping this junk!!!!
0 · Reply
Monkey7779192
Monkey7779192 May. 8 at 12:17 AM
$CVKD Odd here. Being pumped by multiple account by a loser pr a scammer.
0 · Reply
focafoca99
focafoca99 May. 7 at 1:04 PM
$CVKD released its quarter ended March 31, 2026 financial results.
0 · Reply
MaryRichr
MaryRichr May. 7 at 3:46 AM
$CVKD Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-announces-end-phase-123000582.html $DGXX $HUT
0 · Reply
Vaderesking
Vaderesking May. 6 at 12:55 PM
We Post Everyday, it's free, we do not sell anything, we do it to better our skillset. Keep us accountable. $SPY Test is complete, the run occurred and we are mid-week, every fiber of your body should be telling you to take profits and sit out the rest, and that would be the right thing to do. Conversely, watch 727.07, if we stay above continuation is on the table. $NQ Stuck in this zone, needs over 28514.25 or under 24822. $QQQ This 688.3 is key, we need to remain over it. Under I would expect a test of 683.08. $RTY 2872.2 test imminent here, I’m watching $CVKD, needs over $7.
0 · Reply
M00nM00
M00nM00 May. 6 at 10:15 AM
$CVKD Bots spamming boards is a sign of it being a
0 · Reply
DonVigo
DonVigo May. 6 at 9:31 AM
$CVKD $SNDK $DGXX Blocked 🚫
0 · Reply
MaryKeller771
MaryKeller771 May. 6 at 9:12 AM
$CVKD Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-announces-end-phase-123000582.html $IBRX $AMD $SPY
0 · Reply
AliciaVaug
AliciaVaug May. 5 at 10:16 PM
$CVKD Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-announces-end-phase-123000582.html $MU $NVDA
0 · Reply